These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 39191032)
1. Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment. Wei X; Yue L; Zhao B; Jiang N; Lei H; Zhai X Eur J Med Chem; 2024 Nov; 277():116785. PubMed ID: 39191032 [TBL] [Abstract][Full Text] [Related]
2. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal. Cohen KA; Abeel T; Manson McGuire A; Desjardins CA; Munsamy V; Shea TP; Walker BJ; Bantubani N; Almeida DV; Alvarado L; Chapman SB; Mvelase NR; Duffy EY; Fitzgerald MG; Govender P; Gujja S; Hamilton S; Howarth C; Larimer JD; Maharaj K; Pearson MD; Priest ME; Zeng Q; Padayatchi N; Grosset J; Young SK; Wortman J; Mlisana KP; O'Donnell MR; Birren BW; Bishai WR; Pym AS; Earl AM PLoS Med; 2015 Sep; 12(9):e1001880. PubMed ID: 26418737 [TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco. Oudghiri A; Karimi H; Chetioui F; Zakham F; Bourkadi JE; Elmessaoudi MD; Laglaoui A; Chaoui I; El Mzibri M BMC Infect Dis; 2018 Feb; 18(1):98. PubMed ID: 29486710 [TBL] [Abstract][Full Text] [Related]
4. Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases. Bhanushali A; Atre S; Nair P; Thandaseery GA; Shah S; Kuruwa S; Zade A; Nikam C; Gomare M; Chatterjee A Microbiol Spectr; 2024 May; 12(5):e0277023. PubMed ID: 38597637 [TBL] [Abstract][Full Text] [Related]
5. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154 [TBL] [Abstract][Full Text] [Related]
7. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region. Dreyer V; Mandal A; Dev P; Merker M; Barilar I; Utpatel C; Nilgiriwala K; Rodrigues C; Crook DW; ; Rasigade JP; Wirth T; Mistry N; Niemann S Genome Med; 2022 Aug; 14(1):95. PubMed ID: 35989319 [TBL] [Abstract][Full Text] [Related]
8. Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies. Borah P; Deb PK; Venugopala KN; Al-Shar'i NA; Singh V; Deka S; Srivastava A; Tiwari V; Mailavaram RP Curr Top Med Chem; 2021; 21(6):547-570. PubMed ID: 33319660 [TBL] [Abstract][Full Text] [Related]
9. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development. Poce G; Cocozza M; Consalvi S; Biava M Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in the research of heterocyclic compounds as antitubercular agents. Yan M; Ma S ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656 [TBL] [Abstract][Full Text] [Related]
11. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A]. Dai XW; Li CY; Wang NH; Chen SS; Tian LL; Zhao YF; Tao LY; Yang XY; Ding BC; He XX Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1110-1117. PubMed ID: 37914422 [No Abstract] [Full Text] [Related]
12. [Investigation of extensive drug resistance in multidrug resistance tuberculosis isolates]. Bektöre B; Haznedaroğlu T; Baylan O; Ozyurt M; Ozkütük N; Satana D; Cavuşoğlu C; Seber E Mikrobiyol Bul; 2013 Jan; 47(1):59-70. PubMed ID: 23390903 [TBL] [Abstract][Full Text] [Related]
13. Treatment efficacy of drug-resistant tuberculosis in Bashkortostan, Russia: A retrospective cohort study. Yunusbaeva M; Borodina L; Alekseev P; Davydov R; Yunusbaev U; Sharipov R; Bilalov F; Yunusbayev B Int J Infect Dis; 2019 Apr; 81():203-209. PubMed ID: 30794942 [TBL] [Abstract][Full Text] [Related]
14. Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study. Guglielmetti L; Veziris N; Aubry A; Brossier F; Bernard C; Sougakoff W; Jarlier V; Robert J Int J Tuberc Lung Dis; 2018 Jan; 22(1):54-59. PubMed ID: 29297426 [TBL] [Abstract][Full Text] [Related]
15. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Kim HR; Hwang SS; Kim HJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ Clin Infect Dis; 2007 Nov; 45(10):1290-5. PubMed ID: 17968823 [TBL] [Abstract][Full Text] [Related]
16. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Velayati AA; Masjedi MR; Farnia P; Tabarsi P; Ghanavi J; ZiaZarifi AH; Hoffner SE Chest; 2009 Aug; 136(2):420-425. PubMed ID: 19349380 [TBL] [Abstract][Full Text] [Related]
17. Antibiotic resistance acquisition versus primary transmission in the presentation of extensively drug-resistant tuberculosis. O'Toole RF Int J Mycobacteriol; 2022; 11(4):343-348. PubMed ID: 36510916 [TBL] [Abstract][Full Text] [Related]
18. [Management of multidrug-resistant tuberculosis]. Tritar F; Daghfous H; Ben Saad S; Slim-Saidi L Rev Pneumol Clin; 2015; 71(2-3):130-9. PubMed ID: 25153927 [TBL] [Abstract][Full Text] [Related]